You can buy or sell ASND and other stocks, options, ETFs, and crypto commission-free!
Ascendis Pharma A/S American Depositary Shares, also called Ascendis Pharma, is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. Read More The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Hellerup, Capital Region
52 Week High
52 Week Low
Yahoo FinanceMar 12
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock
Ascendis Pharma A/S (ASND) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...
Markets InsiderMar 12
Ascendis Pharma - It's Been All About Growth...
(RTTNews) - Shares of Ascendis Pharma A/S (ASND) closed yesterday's trading at an all-time high of $125.29, and that represents a gain of nearly 100% year-to-date.
Seeking AlphaMar 9
Ascendis Proves Technology Platform With Big Win In Major Indication
Recently, Ascendis Pharma (ASND) announced positive results from its phase 3 Growth Hormone Deficiency (GHD) study. Specifically, its TransCon human growth hormone (hGH) met the primary endpoint in children with growth hormone deficiency (GHD). The main goal was to see if TransCon hGH could prove to be non-inferior to standard daily injection treatment with Genotropin. This provides patients a new option and a more superior way to improve their lives. These results are substantial and this is only the begin...
Expected Mar 27, After Hours